| 主题 |
日期
(日/月/年) |
| 这连结会以新视窗打开一宗本地感染登革热个案(只备英文版) |
29-11-2024 |
| 这连结会以新视窗打开Promethazine hydrochloride (Phenergan) not to be used in children under 6 (Letter to Healthcare Professionals) (只备英文版) |
20-11-2024 |
| 这连结会以新视窗打开Tegretol Oral Suspension 2%: Update to the posology, method of administration, and limitation of use in neonates (Letter to Healthcare Professionals) (只备英文版) |
13-11-2024 |
| 这连结会以新视窗打开Olanzapine: Assessing the potential risks of syndrome of inappropriate secretion of antidiuretic hormone and hyponatremia (Letter to Healthcare Professionals) (只备英文版) |
1-11-2024 |
| 这连结会以新视窗打开Gavreto® (pralsetinib): New warning and precaution of severe and fatal infections (Letter to Healthcare Professionals) (只备英文版) |
30-10-2024 |
| 这连结会以新视窗打开提高警觉预防手足口病 (只备英文版) |
9-10-2024 |
| 这连结会以新视窗打开在假期间提高警觉预防登革热 (只备英文版) |
2-10-2024 |
| 这连结会以新视窗打开Summary Safety Review - Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the potential risks of prolonged or incident diabetic ketoacidosis despite stopping treatment in adult patients with type 2 diabetes (Letter to Healthcare Professionals) (只备英文版) |
27-9-2024 |
| 这连结会以新视窗打开Plaquenil® (Hydroxychloroquine sulfate): Risk of major congenital malformations and new risks of phospholipidosis and aggravation of myasthenia gravis symptoms (Letter to Healthcare Professionals) (只备英文版) |
20-9-2024 |
| 这连结会以新视窗打开Vigilance against Invasive Group B Streptococcus Infection (只备英文版) |
14-9-2024 |
| 这连结会以新视窗打开Lunsumio (mosunetuzumab): New important identified risk of Hemophagocytic Lymphohistiocytosis (Letter to Healthcare Professionals) (只备英文版) |
13-9-2024 |
| 这连结会以新视窗打开EMA recommends measures to minimise the risk of meningioma with medicines containing medroxyprogesterone acetate (Letter to Healthcare Professionals) (只备英文版) |
9-9-2024 |
| 这连结会以新视窗打开一宗本地感染登革热个案 (只备英文版) |
17-8-2024 |
| 这连结会以新视窗打开世界卫生组织宣布猴痘疫情为国际关注的突发公共卫生事件 (只备英文版) |
15-8-2024 |
| 这连结会以新视窗打开Azithromycin and rare risk of cardiovascular death (Letter to Healthcare Professionals) (只备英文版) |
2-8-2024 |
|
这连结会以新视窗打开EMA advises about risks of using weight loss medicine Mysimba with opioids (Letter to Healthcare Professionals) (只备英文版) |
29-7-2024 |
| 这连结会以新视窗打开Thematic Report on Iron Status (Population Health Survey 2020-22) (只备英文版) |
16-7-2024 |
| 这连结会以新视窗打开New recommendations for GLP-1 receptor agonists to minimise risk of aspiration and pneumonia aspiration during general anaesthesia or deep sedation (Letter to Healthcare Professionals) (只备英文版) |
15-7-2024 |
| 这连结会以新视窗打开Nexavar (sorafenib): Assessing the potential risk of tumour lysis syndrome (Letter to Healthcare Professionals) (只备英文版) |
28-6-2024 |
| 这连结会以新视窗打开Warfarin: be alert to the risk of drug interactions with tramadol (Letter to Healthcare Professionals) (只备英文版) |
21-6-2024 |
| 这连结会以新视窗打开一宗可能在本地感染的登革热个案 (只备英文版) |
19-6-2024 |
| 这连结会以新视窗打开CAR T-cell medicines: PRAC identifies risk of secondary malignancies of T-cell origin (Letter to Healthcare Professionals) (只备英文版) |
17-6-2024 |
| 这连结会以新视窗打开 呼吁就百日咳个案增加提高警觉 (只备英文版) |
24-5-2024 |
| 这连结会以新视窗打开 本地季节性流感最新情况 (只备英文版) |
2-5-2024 |
| 这连结会以新视窗打开CHMP recommended new contraindications on the co-administration of Reyataz (Atazanavir) with encorafenib and ivosidenib, and with carbamazepine, phenobarbital, and phenytoin (Letter to Healthcare Professionals) (只备英文版) |
29-4-2024 |
| 这连结会以新视窗打开今年首宗本地感染的登革热个案 (只备英文版) |
26-4-2024 |
| 這連結會以新視窗打開Vigilance against B virus infection and addition of the infection to the list of “Other communicable diseases of topical public health concern” (只备英文版) |
5-4-2024 |
| 这连结会以新视窗打开Ezetrol (ezetimibe) and the risks of drug-induced liver injury and severe cutaneous adverse reactions (Letter to Healthcare Professionals) (只备英文版) |
28-3-2024 |
| 这连结会以新视窗打开Amiodarone: Assessing the potential risk of primary graft dysfunction following heart transplantation (Letter to Healthcare Professionals) (只备英文版) |
28-3-2024 |
| 这连结会以新视窗打开Ibrance (palbociclib): Assessing the potential risk of venous thromboembolism (Letter to Healthcare Professionals) (只备英文版)
|
28-3-2024 |
| 这连结会以新视窗打开Updated warnings of faricimab (Vabysmo): retinal vasculitis risk (Letter to Healthcare Professionals) (只备英文版) |
21-3-2024 |
| 这连结会以新视窗打开Colistin (colistimethate sodium): Assessing the potential risk of pseudo-Bartter syndrome (Letter to Healthcare Professionals)(只备英文版) |
1-3-2024 |
| 这连结会以新视窗打开Vigilance against upsurge of measles(只备英文版) |
29-2-2024 |
| 这连结会以新视窗打开Vigilance against ceftriaxone reduced susceptible Neisseria gonorrhoeae infection |
30-1-2024 |
| 这连结会以新视窗打开Safety-related information for the product Mifegyne (Letter to Healthcare Professionals) (只备英文版) |
25-1-2024 |
| 这连结会以新视窗打开含mifepristone成分药品安全信息 (Letter to Healthcare Professionals) |
24-1-2024 |
| 这连结会以新视窗打开BCMA- and CD19-directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapies: risk of T cell malignancies (Letter to Healthcare Professionals) (只备英文版) |
24-1-2024 |
| 这连结会以新视窗打开Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate in the United Kingdom (Letter to Healthcare Professionals) (只备英文版) |
23-1-2024 |
| 这连结会以新视窗打开Arrival of the 2023/24 Winter Influenza Season in Hong Kong |
11-1-2024 |